TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
For as long as antiretroviral therapy has existed, we have worried about HIV’s ability to mutate around it. Few mutations have commanded as much of our attention, for as long a period of time, as M184V/I. After all, it’s not only one of the seminal NRTI drug resistance mutations; it’s also highly relevant in the modern treatment era, which heavily features the use of dolutegravir alongside the backbone NRTI lamivudine.
The virus in many people living with HIV today harbors archival M184V/I. A key question clinicians have faced is: Can dolutegravir/lamivudine (DTG/3TC) be just as effective in these patients as it is in everyone else?
A new study from Clinical Infectious Diseases gets us as close as we’ve ever been to a firm answer.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.